A Phase 1 Study of the Safety and Tolerability of CTX-10726

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 5 → 8 locations
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 1 of 15 entries
  2. Study sites: 6 to 5v12
  3. Study sites: 5 to 6v11
  4. Site details revised at 1 of 5 sitesv10
  5. Study sites: 4 to 5
    • Start date changed from estimate of May 1, 2026 to May 28, 2026
    v9
Show 4 earlier versionsHide 4 earlier versions
  1. Eligibility criteria expanded, about 210 words
    • Site details revised at 1 of 4 sites
    v8
  2. Start date: Apr 1, 2026 to May 1, 2026
    • Study sites: 3 to 4
    v7
  3. Study sites: 2 to 3v6
  4. Site details revised at 1 of 2 sitesv5
  1. Recruitment opened
    • Study sites: 1 to 2
    v4
  2. Study sites: 0 to 1v3
  3. Primary endpoints revised (3)
    • Secondary endpoints: details revised at 2 of 15 entries
    • Study title shortened, about 3 words
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Compass Therapeutics
6 trials monitored
See 1 trial at risk
Liver Cancer
1,602 trials monitored
See 70 trials at risk
Esophageal Cancer
1,051 trials monitored
See 53 trials at risk
Kidney Cancer
890 trials monitored
See 72 trials at risk
and 1 more disease
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.
Trial Details
NCT Number NCT07419841
Lead Sponsor Compass Therapeutics
Conditions
(from sponsor)		 Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Related terms Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Endometrial Neoplasms
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov